Interim report April - June 2024

SECOND QUARTER (APRIL– JUNE 2024)      

• Order intake SEK 290.3 M (239.2)
• Net sales SEK 318.9 M (239.5)
• Operating profit SEK 79.3 M (18.2)
• Profit after tax SEK 61.4 M (10.9)
• Earnings per share before/after dilution SEK 1.79 (0.32)
• Cash flow from operating activities SEK 154.6 M (67.2)
• Order backlog SEK 1,790.5 M (1,954.9) at the end of the period

HALF-YEAR (JANUARY– JUNE 2024)

• Order intake SEK 528.8 M (445.8)
• Net sales SEK 576.1 M (469.6)
• Operating profit SEK 125.1 M (41.9)
• Profit after tax SEK 98.1 M (28.5)
• Earnings per share before/after dilution SEK 2.86 (0.83)
• Cash flow from operating activities SEK 321.9 M (220.9)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

• Raigmore Hospital in Scotland selects RayCare.
• RaySearch and C-RAD sign collaboration agreement.
• RayCare has been certified to be interoperable with Varian TrueBeam.
• RayStation Used for First-Ever Radiotherapy Treatment with Hitachi’s OXRAY system.
• The New York Proton Center expands their RayStation installation.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

There have been no significant events after the end of the reporting period.

WEBCAST

CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for April-June 2024 in a webcast to be held in English on Friday, August 16, 2024, at 10:00 a.m. CEST.

Link to webcast: RaySearch Q2, 2024

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 16, 2024, at 7:45 a.m. CEST.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.  

RaySearch's software has been sold to over 1,000 clinics in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

* Subject to regulatory clearance in some markets.

Tags: